Search Results

You are looking at 51 - 60 of 309 items for :

Clear All
Full access

Zhubin J. Gahvari, Michael Lasarev, Jens C. Eickhoff, Aric C. Hall, Peiman Hematti, Mark B. Juckett, Vaishalee P. Kenkre and Natalie S. Callander

Background: Obesity, and in particular severe obesity, is increasingly prevalent in the United States. Epidemiological studies have shown an association in multiple myeloma (MM) between obesity and mortality (Teras et al, Br J Haematol 2014

Full access

Kenneth C. Anderson

Multiple myeloma (MM) is an example of a disease that has seen rapid bench-to-bedside translation of novel agents targeting the tumor in its microenvironment, with clinical trials ultimately leading to FDA approval. Remarkably, 16 new treatments

Full access

8 8 Suppl_1 Suppl_1 Introduction: Addressing Challenges in Multiple Myeloma Management in an Era of New Therapeutics Jagannath Sundar MD 02 2010 8 8 Suppl_1 Suppl_1 S-1 S-1 S-3 S-3 0080S-1 10.6004/jnccn.2010.0111 Complications of

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee and Anaadriana Zakarija

include those of the stomach, kidney, uterus, lung, ovary, bladder, and testis. 1 , 21 , 31 In addition, an increased risk of VTE has been observed in certain hematologic malignancies, such as lymphoma, acute leukemia, and multiple myeloma. 1 , 40 , 41

Full access

Nishanth Thalambedu, Waqas Ullah, Ammar Ashfaq, Yasir Khan, Mishal Shaukat and Qian Zhang

Background: The role of panobinostat compared to elotuzumab and ixazomib in patients with multiple myeloma(MM) continues to be debated in the context of its complications. Methods: MedLine and Cochrane databases were queried with different MeSH

Full access

Audrey Demaree, Anthony Hewitt, Ben Eckert and Lik Wee Lee

and routine patient management. MRD assessment is now recommended within several lymphoid cancer NCCN guidelines, including multiple myeloma (MM), ALL, and CLL. The clonoSEQ® Assay (Adaptive Biotechnologies; Seattle, WA) is currently the only FDA

Full access

Tim Luetkens, Sabarinath Venniyil Radhakrishnan, Sandra D. Scherer, Patricia Davis, Erica R. Vander Mause, Michael L. Olson, Sara Yousef, Jens Panse, Yasmina Abdiche, K. David Li, Rodney R. Miles, William Matsui, Alana L. Welm and Djordje Atanackovic

Background: The SLAM receptor CD229/LY9 is strongly expressed on multiple myeloma (MM) cells and is required for their growth, rendering it a potential target for the treatment of MM. Methods: We used antibody phage display to develop the first

Full access

Plasma cell neoplasms are diseases in which abnormal plasma cells or myeloma cells form tumors in the bones or soft tissues of the body. At the NCCN 2019 Annual Congress: Hematologic Malignancies, a panel of experts identified clinical challenges

Full access

Rodger J. Winn

References 1 Singhal S Mehta J Desikan R . Antitumor activity of thalidomide in refractory multiple myeloma . N Engl J Med 1999 ; 341 : 1565 - 1571 . 2 Richardson PG Barlogie B Bertenson J . A Phase 2 study of bortezomib

Full access

Suneel D. Kamath, Sheetal M. Kircher and Al B. Benson III

funded in proportion to their incidences. Multiple myeloma appeared to be proportionally funded, whereas gastrointestinal cancers (colorectal, pancreatic, and liver and bile duct), gynecologic cancers (ovarian, endometrial, and cervical), lung cancer